The Immune System As a Therapeutic Target for Alzheimer's Disease

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Sep 23

PMID 36143476

Authors

Tarek Zieneldien

Janice Kim

Darrell Sawmiller

Chuanhai Cao

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder and is the most common cause of dementia. Furthermore, aging is considered the most critical risk factor for AD. However, despite the vast amount of research and resources allocated to the understanding and development of AD treatments, setbacks have been more prominent than successes. Recent studies have shown that there is an intricate connection between the immune and central nervous systems, which can be imbalanced and thereby mediate neuroinflammation and AD. Thus, this review examines this connection and how it can be altered with AD. Recent developments in active and passive immunotherapy for AD are also discussed as well as suggestions for improving these therapies moving forward.

Citing Articles

Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.

Kloske C, Mahinrad S, Barnum C, Batista A, Bradshaw E, Butts B Alzheimers Dement. 2024; 21(1):e14291.

PMID: 39692624 PMC: 11772715. DOI: 10.1002/alz.14291.

Boosting Acetylcholine Signaling by Cannabidiol in a Murine Model of Alzheimer's Disease.

Khodadadi H, Lopes Salles E, Naeini S, Bhandari B, Rogers H, Gouron J Int J Mol Sci. 2024; 25(21).

PMID: 39519315 PMC: 11546302. DOI: 10.3390/ijms252111764.

Novel Therapeutic Strategies in Alzheimer's Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond.

Tondo G, De Marchi F, Bonardi F, Menegon F, Verrini G, Aprile D J Clin Med. 2024; 13(11).

PMID: 38892809 PMC: 11172489. DOI: 10.3390/jcm13113098.

Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.

Patwekar M, Patwekar F, Khan S, Sharma R, Kumar D Curr Top Med Chem. 2024; 24(19):1665-1682.

PMID: 38644708 DOI: 10.2174/0115680266295495240415114919.

Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification.

Zhong H, Zhou X, Uhm H, Jiang Y, Cao H, Chen Y Alzheimers Dement. 2024; 20(4):2469-2484.

PMID: 38323937 PMC: 11032555. DOI: 10.1002/alz.13691.

References

Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L . Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. DOI: 10.1212/01.WNL.0000159743.08996.99. View

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G . Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016; 8(1):14. PMC: 4822297. DOI: 10.1186/s13195-016-0181-2. View

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

Baruch K, Deczkowska A, David E, Castellano J, Miller O, Kertser A . Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014; 346(6205):89-93. PMC: 4869326. DOI: 10.1126/science.1252945. View

Relkin N . Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol. 2014; 34 Suppl 1:S74-9. DOI: 10.1007/s10875-014-0041-4. View

Hull M, Sadowsky C, Arai H, Le Prince Leterme G, Holstein A, Booth K . Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease. Curr Alzheimer Res. 2017; 14(7):696-708. PMC: 5543567. DOI: 10.2174/1567205014666170117101537. View

Reiss A, Montufar N, DeLeon J, Pinkhasov A, Gomolin I, Glass A . Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans. Neurologist. 2021; 26(2):52-61. DOI: 10.1097/NRL.0000000000000320. View

Marsh S, Abud E, Lakatos A, Karimzadeh A, Yeung S, Davtyan H . The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016; 113(9):E1316-25. PMC: 4780638. DOI: 10.1073/pnas.1525466113. View

10.

Ucar D, Marquez E, Chung C, Marches R, Rossi R, Uyar A . The chromatin accessibility signature of human immune aging stems from CD8 T cells. J Exp Med. 2017; 214(10):3123-3144. PMC: 5626401. DOI: 10.1084/jem.20170416. View

11.

Guo T, Noble W, Hanger D . Roles of tau protein in health and disease. Acta Neuropathol. 2017; 133(5):665-704. PMC: 5390006. DOI: 10.1007/s00401-017-1707-9. View

12.

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

13.

He S, Sharpless N . Senescence in Health and Disease. Cell. 2017; 169(6):1000-1011. PMC: 5643029. DOI: 10.1016/j.cell.2017.05.015. View

14.

Gabbita S, Johnson M, Kobritz N, Eslami P, Poteshkina A, Varadarajan S . Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model. PLoS One. 2015; 10(10):e0137305. PMC: 4593589. DOI: 10.1371/journal.pone.0137305. View

15.

Birkenbihl C, Salimi Y, Frohlich H . Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling. Alzheimers Dement. 2021; 18(2):251-261. DOI: 10.1002/alz.12387. View

16.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

17.

Liu P, Xie Y, Meng X, Kang J . History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduct Target Ther. 2019; 4:29. PMC: 6799833. DOI: 10.1038/s41392-019-0063-8. View

18.

Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M . T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A. 2004; 101(21):8180-5. PMC: 419577. DOI: 10.1073/pnas.0402268101. View

19.

Baruch K, Ron-Harel N, Gal H, Deczkowska A, Shifrut E, Ndifon W . CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc Natl Acad Sci U S A. 2013; 110(6):2264-9. PMC: 3568380. DOI: 10.1073/pnas.1211270110. View

20.

Itagaki S, McGeer P, Akiyama H . Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett. 1988; 91(3):259-64. DOI: 10.1016/0304-3940(88)90690-8. View